-
公开(公告)号：US20130189239A1
公开(公告)日：2013-07-25
申请号：US12597473
申请日：2009-02-26
申请人： Gert Bolt , Brian Berg Stidsen Vandahl , Lars Thim , Henning Ralf Stennicke , Thomas Dock Steenstrup , Shawn Defrees
发明人： Gert Bolt , Brian Berg Stidsen Vandahl , Lars Thim , Henning Ralf Stennicke , Thomas Dock Steenstrup , Shawn Defrees
IPC分类号： C12N9/96
CPC分类号： C12N9/96 , A61K38/00 , A61K47/26 , A61K47/60 , C07K14/755
摘要： The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
摘要翻译： 本发明涉及具有修饰的循环半衰期的B结构域截短的因子VIII分子，所述分子与亲水性聚合物共价共轭。 本发明还涉及获得这种分子的方法以及这种分子的使用。
-
公开(公告)号：US20090252720A1
公开(公告)日：2009-10-08
申请号：US12302167
申请日：2007-05-24
CPC分类号： C12N9/96 , A61K38/00 , A61K47/60 , C12N9/644 , C12Y304/21022
摘要： The invention is related to FIX analogues which have an increased circulation time in the blood stream before activation compared to that that of native FIX (and a week after injection to a patient retains at least about 5% of the FIX activity compared to the initial activity peak value reached after injection). The claimed FIX analogues comprise an inserted cysteine residue which has been further modified by conjugation with a chemical group increasing the molecular weight of the FIX analogue.
摘要翻译： 本发明涉及FIX类似物，其在活化前与血浆中循环时间增加相比，与天然FIX相比（注射至患者一周后，与起始活性相比，FIX活性至少保持约5％ 注射后达到峰值）。 所要求保护的FIX类似物包括插入的半胱氨酸残基，其通过与增加FIX类似物的分子量的化学基团缀合进一步修饰。
-
公开(公告)号：US20080227691A1
公开(公告)日：2008-09-18
申请号：US11910349
申请日：2006-04-03
IPC分类号： A61K38/37 , C07K14/755 , A61P7/00
CPC分类号： C07K14/755 , A61K38/00
摘要： The invention is related to a FVIII analogue which has a circulation time in the blood stream before activation of at least about two times of that of native FVIII and a week after injection to a patient retains at least about 5% of the FVIII activity compared to the initial activity peak value reached after injection. The claimed FVIII analogues comprise a targeted disruption of one or more of the clearance sites in the FVIII molecule by introduction of at least one N-glycosylation site or by introduction of at least one Cys residue within or spatially close to the clearance site in the A2 domain or a combination thereof. The inserted cysteine residues may be further modified by conjugation with a chemical group increasing the molecular weight of the FVIII analogue.
摘要翻译： 本发明涉及FVIII类似物，FVIII类似物在活化至少约二分之一的天然FVIII之前在血流中具有循环时间，并且在注射至患者后一周内保留FVIII活性的至少约5％ 注射后达到初始活动峰值。 要求保护的FVIII类似物包括通过引入至少一个N-糖基化位点或通过引入至少一个Cys残基在或在空间上靠近A2中的清除位点来定位破坏FVIII分子中的一个或多个清除位点 域或其组合。 插入的半胱氨酸残基可以通过与增加FVIII类似物的分子量的化学基团缀合来进一步修饰。
-
公开(公告)号：US09982033B2
公开(公告)日：2018-05-29
申请号：US12597118
申请日：2008-04-30
IPC分类号： C07K14/755
CPC分类号： C07K14/755
摘要： The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.
-
公开(公告)号：US20100120094A1
公开(公告)日：2010-05-13
申请号：US12597118
申请日：2008-04-30
IPC分类号： C12P21/00
CPC分类号： C07K14/755
摘要： The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.
摘要翻译： 本发明涉及生产因子VIII多肽的方法，该方法包括以下步骤：a）在表达所述因子VIII多肽的条件下培养表达因子VIII多肽的哺乳动物细胞，所述培养条件涉及细胞培养基 包括C2结构域配体，和b）通过合适的方法从哺乳动物细胞分离表达的因子VIII多肽。
-
6.发明授权公开(公告)号：US07696318B2
公开(公告)日：2010-04-13
申请号：US11995109
申请日：2006-07-13
CPC分类号： C12N9/647 , C07K14/745 , C12N9/6437 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12Y304/21021
摘要： The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.
摘要翻译： 本发明涉及不含或基本上没有蛋白质污染物的维生素K依赖性蛋白质组合物的方法和方法。 特别地，描述了用于还原或消除蛋白质污染物的方法和手段，也是维生素K依赖性蛋白质。
-
7.发明申请Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host sytems 审中-公开γ-羧化多肽在γ-羧化缺陷宿主系统中的表达公开(公告)号：US20090100533A1
公开(公告)日：2009-04-16
申请号：US11793642
申请日：2005-12-19
IPC分类号： A01K67/027 , C12P21/04
CPC分类号： C12N9/647
摘要： The present invention relates to a novel method for preparing gamma-carboxylated poly-peptides, including coagulation Factors VII, IX, X and Protein C. The present invention also relates to novel host cells and recombinant vectors to be used in this improved method for preparing gamma-carboxylated polypeptides.
摘要翻译： 本发明涉及一种制备γ-羧基化多肽的新方法，包括凝血因子VII，IX，X和蛋白C.本发明还涉及新的宿主细胞和重组载体，用于该改进的制备方法 γ-羧化多肽。
-
8.发明授权公开(公告)号：US08940504B2
公开(公告)日：2015-01-27
申请号：US13418844
申请日：2012-03-13
IPC分类号： C07K14/745 , C12N15/113 , C07H21/04
CPC分类号： C12N9/647 , C07K14/745 , C12N9/6437 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12Y304/21021
摘要： The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.
摘要翻译： 本发明涉及不含或基本上没有蛋白质污染物的维生素K依赖性蛋白质组合物的方法和方法。 特别地，描述了用于还原或消除蛋白质污染物的方法和手段，也是维生素K依赖性蛋白质。
-
9.发明申请公开(公告)号：US20100137570A1
公开(公告)日：2010-06-03
申请号：US12700324
申请日：2010-02-04
IPC分类号： C07H21/04
CPC分类号： C12N9/647 , C07K14/745 , C12N9/6437 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12Y304/21021
摘要： The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.
摘要翻译： 本发明涉及不含或基本上没有蛋白质污染物的维生素K依赖性蛋白质组合物的方法和方法。 特别地，描述了用于还原或消除蛋白质污染物的方法和手段，也是维生素K依赖性蛋白质。
-
10.发明申请Host Cell Protein Knock-Out Cells for Production of Therapeutic Proteins 审中-公开用于生产治疗性蛋白质的宿主细胞蛋白质敲除细胞公开(公告)号：US20120171721A1
公开(公告)日：2012-07-05
申请号：US13418844
申请日：2012-03-13
CPC分类号： C12N9/647 , C07K14/745 , C12N9/6437 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12Y304/21021
摘要： The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.
摘要翻译： 本发明涉及不含或基本上没有蛋白质污染物的维生素K依赖性蛋白质组合物的方法和方法。 特别地，描述了用于还原或消除蛋白质污染物的方法和手段，也是维生素K依赖性蛋白质。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.031 秒)
